Aug 12 (Reuters) - Pfizer ( PFE ) said on Monday its

respiratory syncytial virus (RSV) vaccine Abrysvo generated a

strong immune response in a late-stage study of four groups of

adults aged 18 and older with a compromised immune system.

A single 120 microgram dose of the vaccine generated strong

neutralizing antibodies against both subtypes of RSV, called

RSV-A and RSV-B, across all groups in the study, Pfizer ( PFE ) said.

Abrysvo was well-tolerated in the study and showed a safety

profile consistent with findings from other studies of the

vaccine, it added.

The drugmaker plans to submit the data to regulatory

agencies for review.

The study tested two doses of Abrysvo in 203 adults across

four groups - those with a type of lung cancer, end-stage kidney

disease, autoimmune inflammatory disorder, and solid organ

transplant recipients - all of whom have compromised immunity

and are at risk of developing severe RSV-associated disease.

Pfizer's ( PFE ) vaccine is currently approved for people aged 60

and older and for use in women during the middle of the third

trimester of pregnancy to protect their babies.

RSV typically causes cold-like symptoms but is also a

leading cause of pneumonia in toddlers and older adults, leading

to 177,000 hospitalizations and 14,000 deaths in the United

States annually.

(Reporting by Mariam Sunny in Bengaluru; Editing by Devika

Syamnath)